Overview

A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
0
Participant gender:
All
Summary
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Ranibizumab
Criteria
Inclusion Criteria:

- Diagnosis of wet age-related macular degeneration in at least 1 eye

- Best corrected visual acuity of 20/32 to 20/320 in the study eye and 20/200 or better
in the fellow eye

Exclusion Criteria:

- Hypersensitivity, allergy, or anaphylactic reaction to iodine

- Cataract or refractive surgery within the last 3 months

- History of vitrectomy